<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="438">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04350073</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00105221</org_study_id>
    <nct_id>NCT04350073</nct_id>
  </id_info>
  <brief_title>Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 (LEEP-COVID)</brief_title>
  <official_title>Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 (LEEP-COVID)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This current proposal evaluates the Longitudinal Energy Expenditure and Metabolic Effects in
      Patients with COVID-19 (LEEP-COVID) to understand, guide and optimize our metabolic and
      nutritional care of these high risk patients. As no data exist for the metabolic effects of
      COVID-19 patients, this data is urgently needed and essential to assist in the care of
      COVID-19 patients worldwide. We are uniquely positioned at Duke to perform this research, as
      we are the only US center with 2 of the FDA-approved devices in existence currently capable
      of collecting this vital data to guide the care of COVID-19 patients worldwide.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, no longitudinal data exist describing the metabolic and cardiac effects of
      SARS-CoV-2 (COVID-19) infection. This data is urgently needed to assist in care and promote
      recovery of COVID-19 patients worldwide, and elderly patients who are at higher risk due to
      increased age, pre-existing risk factors (frailty, sarcopenia, malnutrition), and co-morbid
      conditions. Further, new pathologies such as COVID-19-related cardiac dysfunction must be
      described and rapidly identified. Our innovative measurements will provide direct
      non-invasive assessments of the effect of COVID-19 infection on key measures including energy
      expenditure, substrate utilization, muscle mass, cardiac function, mitochondrial function,
      and body composition. In addition, we will be able to provide objective data on key recovery
      intervention requirements including energy/nutritional requirements, effects of nutrition and
      rehabilitation efforts on muscle mass and energy state, and recovery of cardiac, muscle
      function.

      Study Questions: We propose to evaluate longitudinal metabolic and cardiac pathophysiology in
      patients with COVID-19 to understand, guide and optimize our metabolic clinical care during
      acute hospitalization. Further, this data will be essential in providing objective data to
      guide physical recovery interventions including nutrition delivery and physical therapy to
      ensure functional recovery of COVID-19 patients.

      We hypothesize: 1) COVID-19 will lead to significant, EE/metabolic changes, systemic
      mitochondrial dysfunction, significant muscle wasting and loss of function throughout the
      course of illness and during recovery. We hypothesize metabolic needs will initially decrease
      in acute illness and subsequently increase as patients transition from the acute phase of
      COVID illness to recovery phases. This data will guide nutrition and metabolic/clinical care
      in all phases of COVID-19 care where, for example, over-and under-feeding may pose risk to
      patient outcome. We hypothesize loss of muscle mass and physical function occurring in
      COVID-19 will significantly affect nutritional/rehabilitative/recovery of function/QoL needs
      and requires addressing to personalize care to optimize clinical and functional recovery
      efforts in older COVID-19 patients.

      We believe longitudinal detailed indirect calorimetry with the innovative new Q-NRG device,
      cardiac assessment, body composition, and muscle and ultrasound measures in COVID-19 patients
      will play a key role in understanding and treating COVID-19 infection by providing objective
      data on the metabolic, cardiac, volume/fluid status, and nutrition needs of COVID-19 patients
      to the bedside clinician. This will increase our understanding of the pathophysiology of
      COVID-19 and the ability of clinical teams to optimize care and patient outcomes. These
      urgently needed data will lead to key advances in the clinical care of COVID-19 patients
      worldwide.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolic and Nutritional Needs of COVID-19 Patients: Measured by Changes of Resting Energy expenditure(REE) over time, as measured by the indirect calorimetry Q-NRG device</measure>
    <time_frame>Minimum of every other day while in ICU (up to 10 days). Once discharged from ICU minimum of 3x a week until discharge (up to 3 weeks)</time_frame>
    <description>The amount of CO2 produced combined with O2 consumed is called the REE (kcal/day) and is measured by the gases exchanged at the mouth.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic and Nutritional Needs of COVID-19 Patients:Changes of the Respiratory Exchange Ratio (RER) as measured by the indirect calorimetry Q-NRG device</measure>
    <time_frame>Minimum of every other day while in ICU (up to 10 days). Once discharged from ICU minimum of 3x a week until discharge (up to 3 weeks)</time_frame>
    <description>RER (ratio of CO2 produced to O2 consumed is called the respiratory exchange ratio (RER) and is measured by the gases exchanged at the mouth</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac Output and Cardiac Measures (non-invasive) in COVID-19 patients</measure>
    <time_frame>Minimum of every other day while in ICU (up to 10 days). Once discharged from ICU minimum of 3x a week until discharge (up to 3 weeks)</time_frame>
    <description>Non-invasive, accurate calculation of cardiac output and other cardiac function measurements via Fick equation using direct measurement of VO2 &amp; VCO2. As COVID-19 is known to have significant risk of cardiac failure &amp; cardiac death this may allow early detection of cardiac changes that otherwise may not be recognized in these patients who will not routinely have invasive cardiac monitoring (I.e. Swan-Ganz catheter)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle Mass and Quality Changes from COVID-19: Measured via Changes of Intramuscular Adipose Tissue (IMAT) Content From CT Scans of the Psoas at the Level of L3/Th3</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Measures the change over time of (standard of care) CT-derived area of intramuscular muscle mass and adipose tissue in cm2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Mass, Quality, Glycogen Changes in COVID-19: Via Metabolic/Muscle Imaging Derived From Muscle-Specific Ultrasound of Leg/Intercostal/Head Muscles</measure>
    <time_frame>Minimum of every other day while in ICU (up to 10 days). Once discharged from ICU minimum of 3x a week until discharge (up to 3 weeks)</time_frame>
    <description>The change over time of Ultrasound-derived muscle mass, muscle glycogen, and area of intramuscular adipose tissue in % and intramuscular glycogen content (IMGC) from rectus femurs - vastus laterals - intercostalis - temporalis - styloglossys</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Composition in COVID-19 Patients: Measured via Multifrequency Bioimpedance Spectroscopy</measure>
    <time_frame>Minimum of every other day while in ICU (up to 10 days). Once discharged from ICU minimum of 3x a week until discharge (up to 3 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Angle in COVID-19 Patients: Measured via Multifrequency</measure>
    <time_frame>Minimum of every other day while in ICU (up to 10 days). Once discharged from ICU minimum of 3x a week until discharge (up to 3 weeks)</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>COVID-19 ICU Patients</arm_group_label>
    <description>COVID-10 patients with respiratory failure admitted to the ICU</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ICU Patients (Control)</arm_group_label>
    <description>Non-COVID-19 respiratory failure patients requiring mechanical ventilation &gt; 48 h receiving similar ICU standards of care at Duke</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Q-NRG Metobolic Cart Device</intervention_name>
    <description>COVID-19 ICU patients will be measured using the Q-NRG device for up to 30 mins. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.</description>
    <arm_group_label>COVID-19 ICU Patients</arm_group_label>
    <arm_group_label>ICU Patients (Control)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MuscleSound Ultrasound</intervention_name>
    <description>COVID-19 ICU patients will have muscle mass, muscle glycogen, and muscle quality measured at rectus femoris (leg), intercostal, and temporal muscle. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.</description>
    <arm_group_label>COVID-19 ICU Patients</arm_group_label>
    <arm_group_label>ICU Patients (Control)</arm_group_label>
    <other_name>Muscle Mass Ultrasound</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Multifrequency Bioimpedance Spectroscopy</intervention_name>
    <description>COVID-19 ICU patients will have body composition and phase angle measured using Multifrequency Bioimpedance Spectroscopy. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.</description>
    <arm_group_label>COVID-19 ICU Patients</arm_group_label>
    <arm_group_label>ICU Patients (Control)</arm_group_label>
    <other_name>InBody S10 BIA</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Critically ill COVID-19 or non-COVID-19 patients greater or equal to 18 years of age
        patients requiring mechanical ventilation for &gt; 48 hours who are admitted to Duke
        Surgical/Trauma ICU, Medical ICU, Cardiothoracic ICU, and Neuro ICU from admission to
        hospital discharge
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Critically ill COVID-19 patients greater or equal to 18 years of age patients
             requiring mechanical ventilation for &gt; 48 hours who are admitted to Duke
             Surgical/Trauma ICU, Medical ICU, Cardiothoracic ICU, and Neuro ICU from admission to
             hospital discharge

          -  Patients must be enrolled within 72 hours of ICU admission

          -  Control: non-COVID-19 respiratory failure patients requiring mechanical ventilation &gt;
             48 h receiving similar ICU standards of care at Duke

        Exclusion Criteria:

          -  Age less than 18 years old

          -  Fraction of inhaled oxygen (FIO2) &gt; 70%

          -  Positive end expiratory pressure (PEEP) &gt; 10cmH2O

          -  Peak ventilatory pressure &gt; 30cmH20

          -  Presence of air leaks from thoracic drain tube

          -  Changes in vasoactive agent dose (&gt;20%, &lt;1 hr before or during IC)

          -  Agitation or change in sedative/analgesic dose (&gt;20%, &lt;1 hr before and/or during IC)

          -  Change in body temperature (&gt;0.5Â°C, &lt;1 hr before and/or during IC)

          -  Expected duration of ICU stay &lt; 24 hours

          -  Expected survival of the patient &lt; 24 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul E Wischmeyer, MD, EDIC, FASPEN, FCCM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul E Wischmeyer, MD, EDIC, FASPEN, FCCM</last_name>
    <phone>919-681-6437</phone>
    <email>paul.wischmeyer@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeroen Molinger</last_name>
    <phone>919-681-6437</phone>
    <email>Jeroen.molinger@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke University Medial Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Wischmeyer, MD, EDIC, FASPEN, FCCM</last_name>
      <phone>919-681-6437</phone>
      <email>paul.wischmeyer@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jeroen Molinger</last_name>
      <phone>9196816437</phone>
      <email>jeroen.molinger@duke.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 14, 2020</study_first_submitted>
  <study_first_submitted_qc>April 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2020</study_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Respiratory failure</keyword>
  <keyword>metabolic phenotype</keyword>
  <keyword>mitochondrial phenotype</keyword>
  <keyword>cardiometabolic phenotype</keyword>
  <keyword>sarcopenia</keyword>
  <keyword>malnutrition</keyword>
  <keyword>critical care</keyword>
  <keyword>muscle mass</keyword>
  <keyword>cardiac function</keyword>
  <keyword>heart failure</keyword>
  <keyword>energy expenditure</keyword>
  <keyword>nutrition</keyword>
  <keyword>intensive care</keyword>
  <keyword>COVID-19</keyword>
  <keyword>SARS-CoV-2</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

